Just had a look at Note 9 to the Annual Financial Statements - INTANGIBLE ASSETS - it shows an addition to the patents asset of $106,144 during the year and this figure appears in the Annual Cash Flow Statement under Investing Activities. I can't determine for certain whether this is the figure we are looking for but there is some explanation in Note 9 on the method of fair valuation for Admedus Vaccines. Good luck with working that out.
Ann: HSV-2 Interim Results Announcement-AHZ.AX, page-230
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.68 |
Change
0.680(4.53%) |
Mkt cap ! $331.4M | |||
| Open | High | Low | Value | Volume |
| $14.90 | $15.75 | $14.85 | $431.9K | 28.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $15.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.95 | 300 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |